Tarchominskie Zaklady Farmaceutyczne Polfa S.A.

7 trials Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

0 Recruiting

7 Completed trials

1 Countries active

2 Unique IMPs

100% Results reported

Phase I (Other)

Other

Phase I (Other): 1 Other: 6

100%

7 of 7 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cardiac failure 1 Type 2 diabetes mellitus 1

Top IMPs

AMOXICILLIN, CLAVULANIC ACID 1 HEPARIN SODIUM 1

All trials

7 total

Bioequivalence Study of Empagliflozin Ended

2026-525434-33-00 1 country
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on 400 mg / 5 mL amoxicillin + 57 mg… Ended

2025-522562-70-00 1 country
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on two amoxicillin-clavulanic acid f… Ended

2025-521718-24-00 1 country
Pharmacokinetic study of colistimethate sodium Ended

2024-520019-41-00 Phase I (Other) 1 country
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Taromentin® 500 mg + 125 mg film-… Ended

2025-521722-15-00 1 country
A single-dose, open-label, randomized, two-period, two-sequence, crossover pivotal bioequivalence study on Dapagliflozin 10 mg film-coated t… Ended

2024-520212-18-00 1 country
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic aci… Ended

2023-503233-22-00 1 country AMOXICILLIN, CLAVULANIC ACID; HEPARIN SODIUM

Showing 1–7 of 7 trials

← All sponsors A–Z